Biological E, CEPI collaborate for COVID-19 vaccine candidate
Hyderabad: Norway-headquartered CEPI, (Coalition for Epidemic Preparedness Innovations) and city-based Biological E. Limited on Tuesday announced a collaboration to advance the development and manufacture of the latter''s COVID-19 subunit vaccine candidate.
CEPI will initially contribute up to USD five million toward the cost of scaling up the process for manufacturing the vaccine and will explore providing additional funding with a goal of potentially enabling the production of 100 million doses in 2021, Bio.E said in a press release here.
Bio E initiated Phase 1/2 clinical trial in the country last month to evaluate the safety and immunogenicity of the vaccine candidate and expects interim data from the trial to be available in the first quarter of 2021.
CEPI and Bio E are committed to global equitable access of COVID-19 vaccines and have agreed that vaccine output funded by CEPIs investment will be made available for procurement and allocation, if proven to be safe and effective, through the COVID-19 Vaccine Global Access (COVAX) Facility, the release said.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.